Jhonatan Santos de Lima

Mr. Jhonatan Santos de Lima

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2025 in Molecules
Verified
Journal Article
Open access
PDF file
JSJoão Victor Marcelino de Souza
João Victor Marcelino de Souza
NCNatália Caroline Coelho
Natália Caroline Coelho
MBMaria Carolina Oliveira de Arruda Brasil
Maria Carolina Oliveira de Arruda Brasil
LALuana Ribeiro dos Anjos
Luana Ribeiro dos Anjos
RBRenata Barros
Renata Barros
Eduardo CilliEduardo Cilli
Eduardo Cilli
Leishmaniasis is a neglected tropical disease caused by a protozoan of the genus Leishmania, which has visceral and cutaneous forms. The symptoms of leishmaniasis include high fever and weakness, and the cutaneous infection also causes lesions under the skin. The drugs used to treat leishmaniasis have become less effective due to the resistance mechanisms of the protozoa. In addition, the current compounds have low selectivity for the pathogen, leading to various side effects, which results in lower adherence to treatment. Various strategies were developed to solve this problem. The bioconjugation between natural compounds with antimicrobial activity and cell-penetrating peptides could alleviate the resistance and toxicity of current treatments. This work aims to conjugate the cell penetration peptide TAT to the guanidine GVL1. The GVL1-TAT bioconjugate exhibited leishmanicidal activity against Leishmania amazonensis and Leishmania infantum with a high selectivity index. In addition, the bioconjugate was more active against the intracellular enzyme CPP than the individual compounds. This target is very important for the viability and virulence of the parasite within the host cell. Docking studies confirmed the higher interaction of the conjugate with CPP and suggested that other proteins, such as trypanothione reductase, could be targeted. Thus, the data indicated that guanidines conjugated with cell-penetrating peptides could be a good approach for developing antileishmanial molecules.

31 October 2024 in Molecules
Verified
Journal Article
Open access
PDF file
NCNatália Caroline Coelho
Natália Caroline Coelho
DFDEIVYS LEANDRO PORTUONDO FUENTES
DEIVYS LEANDRO PORTUONDO FUENTES
JLJhonatan Santos de Lima
Jhonatan Santos de Lima
AVAngela M. A. Velásquez
Angela M. A. Velásquez
VVValéria Valente
Valéria Valente
MGMarcia Graminha
Marcia Graminha
Leishmaniasis is recognized as a serious public health problem in Brazil and around the world. The limited availability of drugs for treatment, added to the diversity of side effects and the emergence of resistant strains, shows the importance of research focused on the development of new molecules, thus contributing to treatments. Therefore, this work aimed to identify leishmanicidal compounds using a peptide dimerization strategy, as well as to understand their mechanisms of action. Herein, it was demonstrated that the dimerization of the peptide TSHa, (TSHa)2K, presented higher potency and selectivity than its monomeric form when evaluated against Leishmania mexicana and Leishmania amazonensis. Furthermore, these compounds are capable of inhibiting the parasite cysteine protease, an important target explored for the development of antileishmanial compounds, as well as to selectively interact with the parasite membranes, as demonstrated by flow cytometry, permeabilization, and fluorescence microscopy experiments. Based on this, the identified molecules are candidates for use in in vivo studies with animal models to combat leishmaniasis.

27 May 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Gabriel SantoroGabriel Santoro
Gabriel Santoro
NCNatália Caroline Coelho
Natália Caroline Coelho
SBSarah Tolentino Rocha Brandão
Sarah Tolentino Rocha Brandão
JLJhonatan Santos de Lima
Jhonatan Santos de Lima
AVAngela Maria Arenas Velasquez
Angela Maria Arenas Velasquez
Eduardo CilliEduardo Cilli
Eduardo Cilli
Background: Peptides are promising tools in medicine for viral, bacterial, and parasitic infections. MAP1 and MAP2 are peptides with antimicrobial activity. Aiming to increase selectivity, enhance antimicrobial activity, and reduce its cytotoxicity, two bioconjugates (GVL1-MAP2 and GVL1-MAP1) with the guanidine derivative group in the N-terminus position were synthesized. Methods: The peptides and bioconjugates were synthesized by SPPS. The biological activity and inhibition of the CPB enzyme were evaluated. Results: Antileishmanial activity was evaluated, and the bioconjugates exhibited higher activity in both the promastigote and amastigote forms than isolated GVL1 and peptides alone. Discussion: GVL1-MAP2 bioconjugate demonstrated not only the greatest activity against L. amazonensis in the promastigote (IC50 = 3.2 μM) and amastigote (IC50 = 0.6 μM) forms but also prevented the parasite from infecting new host cells, reducing the infection rate by 3-fold compared to the untreated control. Similar results were obtained in L. infantum, with IC50 = 2.5 and 1.0 μM for promastigote and amastigote forms, respectively. In active serum, GVL1-MAP2 continued to show high activity. GVL1-MAP2 also showed bactericidal activity against most strains tested. The bioconjugate GVL1-MAP2 showed lower cytotoxicity than GVL1-MAP1 and amphotericin B in macrophages. Permeabilization studies and enzyme inhibition revealed that the peptide acts via at least two distinct mechanisms, with the primary mechanism targeting the membrane and inner targets as an inhibitor of the CPB enzyme. Conclusions: These data demonstrated that the synthesis of bioconjugates can be a tool for the development of bactericidal and antileishmanial compounds with improved potency and selectivity.

22 October 2026 in ACS Omega
Verified
Journal Article
Open access
JLJhonatan Santos de Lima
Jhonatan Santos de Lima
MMMichele Ferreira da Silva Mela
Michele Ferreira da Silva Mela
JLJuliana Romano Lopes
Juliana Romano Lopes
JPJoão Lucas Bruno Prates
João Lucas Bruno Prates
NCNatália Caroline Coelho
Natália Caroline Coelho
MGMarcia Graminha
Marcia Graminha
Leishmaniasis remains a major neglected tropical disease with limited therapeutic options and increasing concerns regarding toxicity and drug resistance. Cysteine protease B (CPB), a key virulence factor in Leishmania spp., represents an attractive molecular target for the development of new antileishmanial agents. In this study, we designed and synthesized a series of dipeptidyl nitrile derivatives as reversible covalent CPB inhibitors and evaluated their biological activity in vitro and in vivo. Molecular docking performed in covalent mode demonstrated favorable accommodation of the compounds within the CPB active site, with the benzyl-containing derivatives showing the most favorable interactions. Among the series, compound 1 ((S)-tert-butyl (1-((cyanomethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate) exhibited potent inhibition of recombinant LmCPB2.8ΔCTE (IC50 = 4.3 ± 0.2 μM) and strong activity against intracellular amastigotes of Leishmania infantum (EC50 = 3.9 ± 0.5 μM; SI ≈ 77) and Leishmania amazonensis (EC50 = 4.6 ± 1.6 μM; SI ≈ 65), surpassing miltefosine in selectivity. Compound 1 showed no cytotoxicity toward murine macrophages, no hemolytic activity, and good tolerability in the Galleria mellonella model. Oral administration of compound 1 to L. infantum-infected BALB/c mice (0.77 mg/kg/day for 5 days) resulted in a significant reduction in parasite burden in the liver and spleen (≈ 40–55%), even at a 10-fold lower dose than miltefosine. Although alterations in hepatic transaminases were observed, no evidence of renal dysfunction was detected. Collectively, these findings identify dipeptidyl nitriles as promising CPB-targeting scaffolds and position compound 1 as a lead structure for further optimization aimed at enhancing antileishmanial efficacy while minimizing host toxicity.